AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05063240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone text messaging plus prospective motivational interviewing
Description: Interactive weekly mobile phone text messaging plus prospective motivational interviewing at study follow up visits
Study NCT05063240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard infant feeding counselling
Description: Standard infant feeding counselling as part of routine practice at primary healthcare facility
Study NCT05063240 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant feeding counselling
Description: Standard infant feeding counselling as part of routine practice at primary healthcare facility
Study NCT05152420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: FXa Inhibitor
Study NCT04270877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Pill
Description: Treatment with LDN for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
Study NCT05152420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: FXa Inhibitor
Study NCT04270877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Treatment with LDN-placebo for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
Study NCT06285279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FKC288
Description: The autologous dual target BCMA/CD19-CAR-T cell of this study is obtained by infecting T cells with anti-BCMA/CD19-CAR lentiviral vectors.~Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study NCT06010329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutetinib Maleate Capsule
Description: Oral administration
Study NCT06115460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral sitagliptin supplementation
Description: oral sitagliptin supplementation for three months
Study NCT05653427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered intravenously.
Study NCT06127407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib 500mg
Description: Provided as tablets, taken orally as two 250mg tablets once daily.
Study NCT06127407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Provided as tablets, taken orally once daily.
Study NCT05530694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician communication training
Description: The clinician training is a generic, skills- and attitude-based approach for clinicians to acknowledge their decision making conversations with patients that 1) there is more than one option, and 2) patient's views matter in deciding what to do next. This tools-free approach can be used on the spot when needed and is termed fostering choice awareness (FCA). The one-hour training consists of 4 parts: 1) a knowledge session on evidence and guidelines on effective conversations and SDM, 2) video-review of behaviors which foster or hinder choice awareness, 3) clinical simulations in which clinicians practice fostering choice awareness behaviors, and 4) a reminder card for use in future clinic visits. Video clips will be of patient-clinician conversations around treatment decision making to prompt and probe clinicians' experiences, improve understanding, and improve practice.
Study NCT05530694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient activation
Description: The patient activation component consists of three questions patients can ask their clinician to help them become more involved: 1. What are my options?; 2. What are the possible benefits and harms of those options?; 3. How likely are each of those benefits and harms to happen to me? These questions have been used in studies to promote improved communication in a number of conditions including cardiovascular disease, cancer, and women's health.
Study NCT05530694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RA Medication summary guide and RA Choice
Description: RA Choice presents information on FDA-approved RA treatments in a set of cards, which can be used alone or in combination based on a patient's preference, values, and the clinician's experience. The RA medication summary guide describes options for medication, physical therapy, occupational therapy, and ways to stay healthy with diet and exercise. Tool development followed key principles of creating low literacy materials that featured icons, short phrases written in plain language, and included topics of interest to RA patients faced with a medication decision. For the proposed study, we will include a paper-based version of the tool, or a web-based version available for telephone or VA Video Connect (VVC) visits. The tools will be updated to include new FDA-approved therapies (e.g., JAK inhibitors).
Study NCT05979415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apomorphine Cartridge
Description: Staccato Cartridge
Study NCT05979415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apomorphine Cartridge
Description: Staccato Cartridge
Study NCT05348304 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EUDIAMET
Description: A combination of myo-inositol and D-chiro-inositol in the 40:1 ratio, Gymnema sylvestre, alpha-lactalbumin and zinc
Study NCT06397300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral Ultrasound guided erector spinae plane (ESP) block
Description: To perform ESP block in the lateral position bilaterally ,the skin will be disinfected with 70% alchol bilaterally and a linear transducer is placed in a longitudinal parasagittal orientation and erector spinae muscle, trapezius muscle, rhomboid major muscle (rhomboid major muscle is absent below T6 level) and transverse process are visualized and local anesthetic is injected (0.25% bupivacaine 20 ml in each side) in the area between transverse process and erector spinae muscle at T10 level.
Study NCT06397300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quadratus lumborum block
Description: In the lateral decubitus position. Right block will be performed; the patient will then repositioned for the left block. An ultrasound device with a convex probe (5-8 MHz) will be placed in the mid-axillary line just above the iliac crest. Then, scan dorsally to keep the transverse orientation until seeing the aponeurosis of the transverses abdominus muscle and by following this aponeurosis, QL muscle will be visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle. A spinal needle (20G) will be inserted in-plane from the anterior to posterior direction, and the tip of the needle will be advanced anterior to the QL muscle. The target site for injection is the plane between the quadratus lumborum and psoas major muscles. This will be followed by injection of 0.25% bupivacaine 20 ml in each side.
Study NCT06397300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar epidural
Description: under strict aseptic precautions, lumbar epidural was performed for patients in Group III using a 16-gauge Touhy epidural needle by a median approach. The T12 - L1 or L1 - L2 interspaces was chosen for the injection.~The epidural space identified by the loss of resistance technique. The catheter was advanced 4 cm cephalad. When the aspiration test results for blood and cerebrospinal fluid were negative, a test dose of (3 mL) 2% lidocaine with 1: 200,000 adrenaline was given after the placement of the epidural catheter.~Then this will be followed by injection of 0.25% bupivacaine 15 ml as a single injection after induction of general anesthesia.
Study NCT06487117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huafu Shengji Ointment
Description: Huafu Shengji Ointment~1. The experimental group received conventional medical treatment: diabetes-related knowledge education, blood sugar control, blood pressure reduction, blood lipid regulation, antiplatelet drugs, vasodilation, nerve nutrition, and the use of antibiotics.~2. The experimental group receive local debridement: iodophor disinfection, saline cleaning, removal of necrotic tissue, and wound exposure.~3. After debridement, Huafu Shengji Ointment is applied topically with a coverage thickness of 1mm, followed by sterile gauze dressing. The dressing is changed every other day. The treatment period is 4-8 weeks.
Study NCT05016596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: turmeric
Description: Turmeric supplement
Study NCT05016596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT06027515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation Program
Description: Multimodal prehabilitation program consisting of pre-surgical optimization of nutrition, physical function, and sleep health via individualized plans. Participants will also be supplied with Nestle Impact Advances Recovery Immunonutrition Drink.
Study NCT05502029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended translation
Description: Translation extended beyond the preoperative area
Study NCT05502029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard translation
Description: Translation in the preoperative area
Study NCT05029531 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.
Description: two-stage stratification into risk groups: Initially and According to the results of induction therapy MRD-positive patients receive a course of blinatumomab and HSCT.
Study NCT06238739 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control - Standard Strategies for hypothermia prevention
Description: Standard temperature management. Patients underwent one-hour pre- and post-operative warming with hot-air warming blankets at 38°C, without any other preoperative or intraoperative thermal protection measure.
Study NCT06238739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control - Standard Strategies for hypothermia prevention
Description: Standard temperature management. Patients underwent one-hour pre- and post-operative warming with hot-air warming blankets at 38°C, without any other preoperative or intraoperative thermal protection measure.
Study NCT06238739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid warming before infusion and infiltration
Description: Passive Measures: Patients underwent one-hour preoperative warming with hot air warming blankets at 38°C (100.4°F), operating room (OR) temperature was maintained at a minimum of 21°C (69.8°F), aseptic/antiseptic solutions along with infiltration fluid were all warmed to 38°C (100.4°F), and surgical fields were kept as dry as possible.
Study NCT06238739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal convection blanket by water flow (Blanketrol)
Description: Blanketrol: Patients underwent continuous intra-operative temperature protection, using a thermal convection blanket by water flow (Blanketrol®) at 40°C (104°F).
Study NCT06238739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conductive fabric electric warming device (HotDog)
Description: HotDog: Patients underwent permanent intra-operative thermal protection measures with conductive fabric electric warming device (HotDog®) at 40°C (104°F).
Study NCT06167057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin/Gemcitabine
Description: UTUC treatment
Study NCT06167057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: UTUC treatment
Study NCT06487117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethacridine lactate solution
Description: ethacridine lactate solution~1. The control group received conventional medical treatment: diabetes-related knowledge education, blood sugar control, blood pressure reduction, blood lipid regulation, antiplatelet drugs, vasodilation, nerve nutrition, and the use of antibiotics.~2. The control group receive local debridement: iodophor disinfection, saline cleaning, removal of necrotic tissue, and wound exposure.~3. After debridement, the wound is cleaned and disinfected with ethacridine lactate solution, then covered and dressed with sterile gauze. The dressing is changed every other day. The treatment period is 4-8 weeks.
Study NCT04881643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavioural therapy via a digital support
Description: A blended treatment approach to PTSD, blending internet-based CBT with face-to-face sessions with a therapist
Study NCT05788263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuroscience based aproach
Description: exercise for pain
Study NCT06399159 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroidectomy and lymph node dissection
Description: All surgical specimens of thyroidectomy and lymph node dissection were subjected to paraffin-embedded histopathological examination, and postoperative were categorized as with cervical lymph node metastasis and without cervical lymph node metastasis.
Study NCT04690777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: VESTIBULAR EXERCISE
Description: OCULAR AND MOVEMENT EXERCISES
Study NCT04690777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MULTICOMPONENT EXERCISE
Description: exercises includes strengthening, cardiovascular training, flexibility and balance
Study NCT06012227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: kent'erbas cheese study
Description: Nutritional intervention with kent'erbas pecorino from extensive farming with crossover and industrial pecorino from intensive farming
Study NCT06012227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: kent'erbas cheese study
Description: Nutritional intervention with kent'erbas pecorino from extensive farming with crossover and industrial pecorino from intensive farming
Study NCT04905342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1805
Description: orally, once daily on Period 1 and Period 3 (or Period 2 and Period 4) (NVP-1805 80/10/20.8mg)
Study NCT04905342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1805-R1and NVP-1805-R2
Description: orally, once daily on Period 1 or Period 3 (or Period 2 and Period 4) (NVP-1805-R1 80mg, NVP-1805-R2 10/20.8mg)
Study NCT06262984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Play
Description: The researcher will demonstrate the nasopharyngeal swabbing process on the doll with the children who have chosen a therapeutic play group, using a therapeutic play method, and play with the child. The Children's Emotional Manifestation Scale (CEMS) will be evaluated and scored by the researcher and the observing nurse.
Study NCT05016960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep-SMART
Description: Sleep-SMART will be a treatment for insomnia that will follow the standard 6 session 50-minute CBT-I format and will deliver CBT-I treatment along with training in select CogSMART strategies to enhance intervention learning and adherence. It will be delivered via video-based telehealth.
Study NCT06258252 — intervention group
Intervention type: OTHER
Intervention: Effect of BCAAs metabolic dysfunction on cardiac function in sepsis
Description: Effect of BCAAs metabolic dysfunction on cardiac function in sepsis
Study NCT05220423 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sms and emails reminders
Description: 6 reminders encouraging influenza vaccination on top of the National annual communication campaign organized by the French Health System authorities
Study NCT05220423 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No reminders
Description: no reminders on top of the National annual communication campaign organized by the French Health System authorities
Study NCT04325880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron 50 MG
Description: Patients in this arm will receive Mirabegrone 50 MG once daily
Study NCT04325880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Patients in this arm will receive Tamsulosin o.4 MG once daily
Study NCT04325880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate 10 MG
Description: Patients in this arm will receive Solifenacin Succinate 10 MG once daily
Study NCT04325880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Patients in this arm will receive placebo oral tablet once daily
Study NCT05662969 — intervention group
Intervention type: DEVICE
Intervention: MACHINE PERFUSION
Description: Different outcomes of MP use in low/mid-volume and high-volume LT centres
Study NCT05888519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FID123300 ocular lubricant
Description: Investigational ocular lubricant
Study NCT05888519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FID123301 ocular lubricant
Description: Investigational ocular lubricant
Study NCT05888519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FID122505 ocular lubricant
Description: Comparator ocular lubricant
Study NCT05902624 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hepatitis B Virus Vaccine(HBV)
Description: Hepatitis B Virus Vaccine(HBV)
Study NCT04941872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT
Description: Each subject receive a single intravenous injection of 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2, and undergo PET/CT imaging within the specified time.
Study NCT05029284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: teleABLE
Description: Participants will be guided to self-monitor their daily activities, schedule personally meaningful non-sedentary activities, collaboratively problem solve to overcome barriers to the activity, and self-assess their progress. Participants may be asked to self-monitor their activity levels and complete planned activities between sessions.
Study NCT05540431 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Activated Charcoal
Description: RCT
Study NCT05540431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotic
Description: RCT
Study NCT05540431 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: RCT
Study NCT05761847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Medication Therapy Management (pMTM)
Description: The pMTM intervention is comprised of 3 activities: comprehensive review of the medication regimen; optimization of the medication regimen; and creation of the medication action plan.
Study NCT05877989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acid
Description: Amino acid enteral and/or parenteral nutrition either enteral or parenteral to target a total protein delivery of 2.0g/kg/day.
Study NCT05877989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: The physical exercise intervention will be delivered by trained nursing staff, and started as close to the time of randomization as feasible (within 24hours of randomization). The intervention group will receive exercise sessions, for up to 20 min duration (as tolerated by patient).The implementation of physical exercise intervention will be protocolized to provide passive exercise early before weaning and shift to active exercise after weaning and also graduated resistance during each session and between daily sessions.
Study NCT04732793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyruan ONE®
Description: For use as a symptomatic treatment of osteoarthritis (OA) of the knee
Study NCT04732793 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Durolane®
Description: For use as a symptomatic treatment of osteoarthritis (OA) of the knee
Study NCT04329065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
Description: Given ID
Study NCT04329065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given via infusion
Study NCT04329065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT04329065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV
Study NCT06399042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SP5M002 inj
Description: pre-filled syringe
Study NCT06399042 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synovian inj
Description: pre-filled syringe
Study NCT05748899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ujjayi pranayama
Description: this group will receive home-based daily ujjayi pranayama for six weeks (fifteen minutes in the morning and 15 min in the evening, this training will be online supervised).
Study NCT05805449 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Surgery
Description: Control patients will receive usual standard of care surgical repair of their complex fistula by LIFT or advancement flap technique without any biologic adjunct.